PT  - JOURNAL ARTICLE
AU  - Dhruvkumar Laheru
AU  - Anna Antony
AU  - Sueli Carneiro
AU  - Vito Di Lernia
AU  - Amit Garg
AU  - Thorvardur Jon Love
AU  - Karla del Rocio Macias Garcia
AU  - José Alexandre Mendonça
AU  - Sandeep Mukherjee
AU  - Rodica Olteanu
AU  - Lourdes Perez-Chada
AU  - Cheryl F. Rosen
AU  - Rachel Tannenbaum
AU  - Michel Alexandre Yazbek
TI  - Management of Nail Disease in Patients With Psoriatic Arthritis: An Updated Literature Review Informing the 2021 GRAPPA Treatment Recommendations
AID  - 10.3899/jrheum.220313
DP  - 2023 Mar 01
TA  - The Journal of Rheumatology
PG  - 433--437
VI  - 50
IP  - 3
4099  - http://www.jrheum.org/content/50/3/433.short
4100  - http://www.jrheum.org/content/50/3/433.full
SO  - J Rheumatol2023 Mar 01; 50
AB  - Objective Nail psoriasis is common, impairs fine motor finger functioning, affects cosmesis, and is associated with a lower quality of life. This review updates the previous Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) treatment recommendations for nail psoriasis.Methods This systematic literature review of the PubMed, MEDLINE, Embase, and Cochrane databases examined the updated evidence since the last GRAPPA nail psoriasis treatment recommendations published in 2014. Recommendations are based on preformed PICO (Patient/Population - Intervention - Comparison/Comparator - Outcome) questions formulated by an international group of dermatologists, rheumatologists, and patient panel members. Data from this literature review were evaluated in line with Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology.Results Overall, there is insufficient evidence to make any recommendation for the use of topical corticosteroids, topical calcipotriol, topical tazarotene, topical cyclosporine, dimethyl fumarates/fumaric acid esters, phototherapy, and alitretinoin. There is a low strength of evidence to support the use of calcipotriol and corticosteroid preparations, topical tacrolimus, oral cyclosporine, oral methotrexate, intralesional corticosteroids, pulsed dye laser, acitretin, Janus kinase inhibitors, and apremilast.Conclusion The highest strength of supporting evidence is for the recommendation of biologic agents including tumor necrosis factor inhibitors, and interleukin 12/23, 17, and 23 inhibitors.